These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Lilly, and Merck.

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for gastroesophageal cancers. Each event will employ an identical format that will include the following elements:

• Moderator Dr Neil Love and a featured participating clinical investigator
• Discussion of participating faculty treatment recommendations
• Review of available clinical research findings
• Community oncologist video case presentations
• Interactive audience polling and extensive Q&A

MODULE 1: Optimal Management of HER2-Negative Advanced Gastric and Gastroesophageal Junction (GEJ) Cancer

MODULE 2: Treatment Approaches for Newly Diagnosed and Relapsed HER2-Positive Advanced Gastric/GEJ Cancer

MODULE 3: Current and Future Management of Localized Esophageal Cancer

MODULE 4: Clinical Implications of Recent Advances in the Treatment of Metastatic Esophageal Cancer

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of gastroesophageal cancers.

Learning Objectives

• Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to personalize the selection of first-line therapy for locally advanced or metastatic gastric, gastroesophageal junction (GEJ) and esophageal cancer.
• Describe the published research data with the use of anti-PD-1 antibodies alone or in combination with other systemic therapies in the management of gastric, GEJ and esophageal cancer, and integrate these strategies into nonresearch treatment algorithms.
• Optimally incorporate available therapeutic agents and regimens into the management of HER2-negative metastatic gastric, GEJ and esophageal cancer that has progressed on front-line therapy.
• Appraise clinical trial findings supporting the use of adjuvant anti-PD-1 antibody therapy for patients with resected esophageal or GEJ cancer who have received neoadjuvant chemoradiation therapy and have residual pathologic disease, and discern the clinical applicability of this strategy.
• Recall available data with novel HER2-targeted agents and strategies for newly diagnosed and previously treated HER2-overexpressing gastric/GEJ cancer, and identify appropriate patients for these approaches.
• Recognize common and rare side effects associated with approved and investigational agents used in the care of patients with gastroesophageal cancers, and apply this information to develop appropriate and effective supportive management plans.
• Review the rationale for, available data with and ongoing research evaluating novel agents and strategies for gastroesophageal cancers, and effectively prioritize clinical trial opportunities for eligible patients.

CE Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Klempner has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Janjigian — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Basilea Pharmaceutica Ltd, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Imugene, Lilly, Merck, Merck Serono, MJH Life Sciences, Pfizer Inc, Rgenix, Seagen Inc, Zymeworks Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Cycle for Survival, Fred's Team, Genentech, a member of the Roche Group, Lilly, Merck, National Cancer Institute, Rgenix, US Department of Defense; Stock Options: Rgenix. Dr Strickler — Advisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, GlaxoSmithKline, Inivata, Natera Inc, Pfizer Inc, Seagen Inc, Silverback Therapeutics, Viatris; Consulting Agreement: Mereo BioPharma; Contracted Research: AbbVie Inc, Amgen Inc, AStar D3, Bayer HealthCare Pharmaceuticals, Curegenix, Daiichi Sankyo Inc, Erasca, Genentech, a member of the Roche Group, Gossamer Bio, Nektar, Sanofi Genzyme, Seagen Inc, Silverback Therapeutics; Data and Safety Monitoring Board/Committee: AbbVie Inc, Pionyr Immunotherapeutics. Prof Van Cutsem — Advisory Committee: AbbVie Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biocartis, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, GlaxoSmithKline, Halozyme Inc, Helsinn Healthcare SA, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck KGaA, Merck Sharp & Dohme LLC, Mirati Therapeutics Inc, Novartis, Pierre Fabre, Roche Laboratories Inc, Seagen Inc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Terumo Medical Corporation, TRIGR (trial), Zymeworks Inc; Research Grants to Institution: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Merck Sharp & Dohme LLC, Novartis, Roche Laboratories Inc, Servier Pharmaceuticals LLC. Dr Yoon — Advisory Committee: Amgen Inc, Daiichi Sankyo Inc; Consulting Agreements: ALX Oncology, Astellas, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol-Myers Squibb Company, MacroGenics Inc, Merck, OncXerna Therapeutics Inc, Zymeworks Inc; Contracted Research: Bristol-Myers Squibb Company, Merck; Speakers Bureau: BeiGene Ltd.

SURVEY PARTICIPANTS — Peter C Enzinger, MD — Consulting Agreements: ALX Oncology, Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol-Myers Squibb Company, Chimeric Therapeutics, Celgene Corporation, Coherus BioSciences, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, IDEAYA Biosciences, Istari Oncology, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Ono Pharmaceutical Co Ltd, Servier Pharmaceuticals LLC, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Turning Point Therapeutics Inc, Xencor, Zymeworks Inc. Manish A Shah, MD — No relevant conflicts of interest to disclose.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, Lilly, and Merck.